Incylix Bio
Incyclix Bio | Innovative Oncology Therapeutics
United States · $46.3M raised
- Headquarters
- North Carolina
- Business Model
- B2B
- Website
- incyclixbio.com
- Total Funding
- $46.3M
- Last Round
- $5.0M Extension RoundApr 2026
- Rounds
- 3
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Incyclix Bio advances precision treatments that target the aberrant proliferation driving many cancers. Its lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 inhibitor in clinical development. The company applies its understanding of cyclin-dependent kinases and their role in the cell cycle to targets across ovarian, breast, and lung cancers.
Summary
Incylix Bio is a Biotech company based in United States. It has raised $46.3M in total across 3 rounds, most recently a $5.0M Extension Round in Apr 2026. Investors include Hatteras Venture Partners, Boxer Capital and RA Capital Management.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Apr 2026
Sign up to see all 3 events
Funding: Series B through Extension Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/incylix-bio"><img src="https://indexed.vc/api/badge/company/incylix-bio" alt="Incylix Bio on Indexed.vc" width="260" height="76" /></a>